Towards chemotherapy-free treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia

Affiliations

¹ Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands. Electronic address: j.m.boer-20@prinsesmaximacentrum.nl.
² Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Comment

Judith M Boer et al. Lancet Haematol. 2023 Jan.

. 2023 Jan;10(1):e3-e5.

doi: 10.1016/S2352-3026(22)00351-9. Epub 2022 Nov 16.

¹ Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands. Electronic address: j.m.boer-20@prinsesmaximacentrum.nl.
² Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

No abstract available

Conflict of interest statement

IMvdS received research support from Amgen. JMB declares no competing interests.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36402146 Clinical Trial.